With this “new” undertaking, InSightec has invested as much as $200 million for the company’s research and development efforts. To date, InSightec is credited for more than 90 patents, aside from then pending application for addition intellectual properties.
The MRgFUS technology is a combination of two of the most well-known technologies to come up with this breakthrough therapy. MRgFUS is useful for non-invasive surgery that does not use anesthesia. Outpatient procedures that use MRgFUS last between 2 and 4 hours only. On normal cases, patients return to their normal activities within one day after a procedure. MRgFUS minimizes many medical complications such as infections, transfusions and adverse surgical events. MRgFUS promotes green surgery by minimizing the spread of biohazards.
InSightec carries two major products: the ExAblate® Neuro and the ExAblate® OR. ExAblate® Neuro helps treat brain disorders through a thousand-element helmet-like transducer. This product is used for treating Neuropathic pains, Parkinson’s disease and Essential tremor. InSightec is doing clinical tests for the possibility of using ExAblate® Neuro to treat brain tumors.
ExAblate® OR is used to treat body applications. The product offers options for commercialization or research treatment for a wide range of medical conditions such as adenomyosis, uterine fibroids, pain palliation of bone metastases and prostate and breast cancers.
For a continuing improvement of its products and services, InSightec clinically collaborates with the leading medical research groups and hospitals across the globe. Together, InSightec and its partners conduct sponsored trials to collect clinical data that would help advance InSightec’s technology and continue to develop the widest spectrum of new clinical applications.
InSightec is based in Tirat Carmel, Israel. Its US offices are located in Dallas, Texas and Milwaukee, Wisconsin. InSightec has operations in Europe and in Asia.
No comments:
Post a Comment